Skip to content
OpenCapital
Get started

Amneal Pharmaceuticals, Inc. AMRX Injectable — Net revenue

Other product segments

Subtotal dosage forms
$417.92M+1.1%
Oral solid
$171.1M-4.4%
Subtotal therapeutic classes
$133.27M+23.1%
Distribution
$89.15M-15.0%
Central nervous system
$83.38M+23.3%
Transdermal
$73.96M+71.8%
Government label
$59.95M+19.6%
Other dosage forms
$46.61M-17.4%
Auto-Injector
$41.91M-13.0%
Hormonal / allergy
$35.93M+5.1%
Biosimilar
$22.3M-21.9%
Other therapeutic classes
$13.95M+115%
Oral liquid
$12.09M-48.6%
Institutional
$9.82M-10.8%
International
$5.32M+331%

Similar metrics at other companies

Baxter International logo
BAXInjectables & Anesthesia — Net Sales
$301M-10.1%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$2.99B+8.2%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Incyte logo
INCYNet sales — Total revenues
$1.1B+19.8%
Biogen logo
BIIBProduct revenue, net — Total Revenue
$1.75B+1.5%

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%
Enterprise value$7.55B+33.4%
P/E42.4×—
P/S1.7×+0.5×

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s injectable — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s injectable — net revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported injectable — net revenue of $49.94M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s injectable — net revenue changed year-over-year?
Amneal Pharmaceuticals, Inc.'s injectable — net revenue increased by 43.5% year-over-year, from $34.79M to $49.94M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s injectable — net revenue?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s injectable — net revenue has grown at a -5.1% compound annual growth rate (CAGR), from $188.94M to $161.24M.
What does injectable — net revenue mean?
This metric represents the total gross sales generated from the injectable pharmaceutical product line after accounting for returns, allowances, and rebates. It serves as a key indicator of the market demand and commercial performance for sterile, parenteral dosage forms within the company's portfolio. Monitoring this revenue stream helps investors assess the competitive positioning and growth trajectory of the company's specialized injectable manufacturing capabilities.